Sunshine Biopharma Inc. (SBFM) - Dilution Analysis

8-K filing: Sunshine Biopharma Inc. completed a public offering of common units and pre-funded units, resulting in approximately $6 million in gross proceeds. ($6.0M proceeds)

10-Q filing | 4.9M shares outstanding

S-1 filing: The Company is conducting a best efforts secondary offering of units consisting of common stock and warrants, as well as pre-funded units consisting of pre-funded warrants and common warrants.

10-K filing | 4.9M shares outstanding

10-Q filing | 4.6M shares outstanding

10-Q filing | 4.5M shares outstanding

POS AM filing: Sunshine Biopharma Inc. is offering 15,577,965 shares of common stock issuable upon exercise of outstanding Series B Warrants and also includes information regarding previous offerings.

10-Q filing | 4.6M shares outstanding

8-K filing: Sunshine Biopharma Inc. completed a registered direct offering of 928,404 shares of its common stock and pre-funded warrants to purchase up to 260,000 shares, at a price of $2.07 per share and $2.06999 per warrant, respectively, resulting in net proceeds of approximately $1.8 million for general corporate purposes.

10-K filing | 2.7M shares outstanding

S-3 filing: Sunshine Biopharma Inc. may offer common stock, preferred stock, warrants, rights, or a combination of these securities, or units, for an aggregate initial offering price of up to $100,000,000.

POS AM filing: Sunshine Biopharma Inc. is offering 12,394,062 shares of common stock issuable upon exercise of outstanding Series B Warrants.

10-Q filing | 2.0M shares outstanding

10-Q filing | 1.1M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 18,945,052 → 947,252

10-Q filing | 18.9M shares outstanding

8-K filing: Stock split 1-for-100 | Outstanding: 99,452,865 → 994,528

10-K filing | 99.5M shares outstanding

8-K filing: Sunshine Biopharma, Inc. sold 100,000 shares of Series "B" Preferred Stock to its CEO for $10,000 on March 4, 2024. ($0.01M proceeds)

8-K filing: Sunshine Biopharma, Inc. closed a public offering of 71,428,571 units consisting of common units and pre-funded units at a price of $0.14 and $0.139 respectively, with Aegis Capital Corp. as the underwriter, resulting in gross proceeds of approximately $10.0 million before deductions. ($3.7M proceeds)

8-K filing: Sunshine Biopharma, Inc. repurchased warrants to purchase 11,904,762 shares of common stock for $2,361,596 and warrants to purchase 9,725,690 shares of common stock for $778,055. ($3.14M proceeds)

S-1/A filing: This is an S-1/A filing for Sunshine Biopharma, Inc. registering the offer and sale of units consisting of common stock or pre-funded warrants, Series A warrants, and Series B warrants, with Aegis Capital Corp. acting as underwriter.

S-1 filing: Sunshine Biopharma, Inc. is offering units, each consisting of one share of common stock, one-tenth of a Series A warrant, and two-tenths of a Series B warrant, and pre-funded warrants to certain purchasers.

10-Q filing | 25.7M shares outstanding

10-Q filing | 25.4M shares outstanding

S-3 filing: The selling stockholder is offering on a resale basis an aggregate of 17,857,143 shares of common stock.

8-K filing: Sunshine Biopharma, Inc. closed a private placement on May 16, 2023, selling 2,450,000 shares of common stock, investor warrants to purchase up to 11,904,762 shares, and 3,502,381 pre-funded warrants, for gross proceeds of approximately $5.0 million. ($5.01M proceeds)

10-Q filing | 22.0M shares outstanding

10-K filing | 22.6M shares outstanding

10-Q filing | 22.6M shares outstanding

8-K filing: Sunshine Biopharma, Inc. acquired all of the issued and outstanding shares of Nora Pharma in consideration of $30,000,000 CAD, which includes the issuance of 3,700,000 shares of Sunshine Biopharma's common stock. ($3.65M proceeds)

10-Q filing | 18.9M shares outstanding

S-3 filing: Selling stockholders are offering an aggregate of 14,588,535 shares of common stock on a resale basis, including shares issuable upon exercise of warrants.

10-Q filing | 16.5M shares outstanding

8-K filing: Sunshine Biopharma, Inc. closed a private placement on April 28, 2022, selling common stock, pre-funded warrants, and investor warrants for gross proceeds of approximately $19.5 million.

S-3 filing: This is an S-3 filing for the resale of common stock by selling stockholders.

10-K filing | 7.1M shares outstanding

8-K filing: Sunshine Biopharma, Inc. entered into a Securities Purchase Agreement for a private placement, selling 2,301,353 shares of common stock and 1,302,251 pre-funded warrants, along with warrants to purchase additional shares, resulting in gross proceeds of approximately $8 million before transaction expenses. ($8.0M proceeds)

8-K filing: Sunshine Biopharma, Inc. redeemed 990,000 shares of Series B Preferred Stock held by the Company's chief executive officer, Dr. Steve N. Slilaty, for a redemption price equal to the stated value of $0.10 per share. ($0.1M proceeds)

8-K filing: Sunshine Biopharma, Inc. closed a firm commitment underwritten public offering of 1,882,353 units at $4.25 per Unit, with each unit consisting of one share of common stock and two warrants, for gross proceeds of $8 million. ($8.0M proceeds)

S-1/A filing: This is an S-1/A filing for an offering of common stock, pre-funded warrants, and warrants underwritten by Aegis Capital Corp.

8-K filing: Stock split 1-for-200 | Outstanding: 2,591,241 → 12,956

S-1/A filing: This S-1/A filing relates to an offering of common units, pre-funded units, and warrants with Aegis Capital Corp. acting as underwriter with the intention to use the net proceeds of this offering for drug development activities and general corporate purposes, including working capital, and for debt repayment.

S-1/A filing: This S-1/A filing outlines an offering of 1,886,792 units, each consisting of one share of common stock and one warrant exercisable for one share of common stock at an exercise price of $5.30, and other corporate matters including securities, lock-up agreements, and financial information.

8-K filing: The company issued 2,904,833 shares of common stock to RB Capital Partners, Inc. in connection with the conversion of $1,361,000 in convertible debt at an average conversion price of $0.47 per share. ($1.36M proceeds)

10-Q filing | 508.5M shares outstanding

S-1 filing: This S-1 filing details an offering of units, each consisting of one share of common stock and one warrant, with Aegis Capital Corp. as the underwriter.

10-Q filing | 478.5M shares outstanding

10-Q filing | 438.8M shares outstanding

10-K filing | 346.4M shares outstanding

10-Q filing | 304.4M shares outstanding

10-Q filing | 191.7M shares outstanding

10-Q filing | 59.7M shares outstanding

10-K filing | 35.3M shares outstanding